Anavex Life Sciences Corp. (AVXL)
Develops drug treatments for Alzheimer's, Parkinson's, and other brain diseases
$2.57+0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-77.1%
The outlook
AVXL is trading near its 52-week low and sits below both its 50- and 200-day moving averages, signaling a weak near-term trend. Analyst coverage shows a wide gap, with the average price target suggesting substantial upside from current levels, though the overall StockGlow score leans bearish. The stock remains under pressure despite the optimistic consensus targets.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range3% of the way from its 52-week low to high
Price targetAvg target +678% vs current price
Market cap
$238.2M
52-wk high
$12.68
52-wk low
$2.26
50-day avg
$2.63
200-day avg
$4.19
Trailing P/E
—